Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 11Unknown 2Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 63Lymphoid 38Other hematologic neoplasm 20Thoracic 8Gastrointestinal 6Dermatologic 6Myeloid 4Genitourinary 4Other solid neoplasm 3Classical hematology 2CNS 2Breast 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Brain Neoplasms 2Oligodendroglioma 1Melanoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 80Radiotherapy 41Bevacizumab 35Radiosurgery 23Magnetic Resonance Spectroscopy 20Cyclophosphamide 17Radiation 14Irinotecan 13Carboplatin 12Topotecan 11Nivolumab 11Lomustine 11Filgrastim 10Everolimus 10Etoposide 10Erlotinib Hydrochloride 10pembrolizumab 9Radiotherapy, Intensity-Modulated 9Ipilimumab 9Granulocyte Colony-Stimulating Factor 8Carmustine 8antineoplaston AS 2-1 7antineoplaston A10 7Surgical Procedures, Operative 7Mental Status and Dementia Tests 7Isotretinoin 7Granulocyte-Macrophage Colony-Stimulating Factor 7sargramostim 6Vincristine 6TPI-287 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Bortezomib × CNS × Clear all
NCT00006773 2013-01-24

Bortezomib in Treating Patients With Recurrent Glioma

National Cancer Institute (NCI)

Phase 1 Terminated
42 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00512798 2012-10-02

Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

Vanderbilt-Ingram Cancer Center

Phase 1/2 Terminated
47 enrolled 9 charts
CNSDermatologic

Brain Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡